Chemomab Therapeutics Ltd ADR (CMMB) Stock Price, Quote & News

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therape...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 77 331 0156

Website: www.chemomab.com

Address:

Building 7, Kiryat Atidim, Tel Aviv-Yafo, Israel

DLTT4489 Apr. 4 at 12:54 AM

$CMMB actually ask @shreyvakil @Snptrader and others who trapped people here for years. That big guy who i know is filthy monster. He gets paid by companies to drags people to stocks.

0 · Reply

DLTT4489 Apr. 4 at 12:51 AM

$CMMB please stay long until you declare bankruptcy.

0 · Reply

JoeShmoDoe Apr. 3 at 6:09 PM

$CMMB

0 · Reply

Tigerfromasia Apr. 3 at 6:54 AM

$CMMB Alfasigma

0 · Reply

DLTT4489 Apr. 2 at 1:34 PM

$CMMB what a massive volume 71🤣🤣🤣

0 · Reply

DLTT4489 Apr. 2 at 12:07 PM

$CMMB get ready for blood bath 🛁

0 · Reply

Rolex53 Apr. 1 at 4:29 PM

$CMMB A look at $RGC encouraging $CMMB where a company with good catalog can take off from less than a dollar to the moon IMHO.

2 · Reply

Snptrader Mar. 31 at 7:04 PM

$CMMB could see a nice rebound here as investors pivot back into the name after the war is "ending" and the geopolitical risk is dampened (giving this is an Israeli company). Not much for sale up to $1.86. Of course news of FDA P3 acceptance or BTD status would be welcomed

1 · Reply

DLTT4489 Mar. 31 at 4:38 PM

$CMMB True🤪🤪👇👇

0 · Reply

Stockhunter008 Mar. 31 at 1:24 PM

$CMMB Check out the Centessa acquisition deal that was announced today. Centessa is a pre-clinical platform company with zero revenue. This is the type of deal that the $CMMB CEO is waiting for. increasing the shares outstanding will enable a partnership with an equity component. with the money, start the PSC phase 3 and do the SSC phase 2, thus proving the platform capability of Nebokitug. https://www.axios.com/pro/biotech-deals/2026/03/31/eli-lilly-centessa-pharmaceuticals-7-8b

1 · Reply